ERBB2 and gastroesophageal junction adenocarcinoma: The effectiveness of trastuzumab in combination with capecitabine and oxaliplatin as a first-line treatment for advanced gastric or GEJ adenocarcinoma with HER2 overexpression (n = 45) was assessed in the HERXO Phase II trial [44].